A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver CancerPLCor Biliary Tract Carcinoma (BTC)

Trial Profile

A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver CancerPLCor Biliary Tract Carcinoma (BTC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Camrelizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Rivoceranib
  • Indications Biliary cancer; Liver cancer
  • Focus Adverse reactions
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 24 Jul 2018 The protocol was amended to include patients with Biliary Tract Carcinoma (BTC) and GEMOX regimen.
    • 24 Jul 2018 Planned number of patients changed from 36 to 152.
    • 24 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top